Population Pharmacokinetic Modeling for Ceftazidime‐Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older

Ceftazidime‐avibactam is a novel β‐lactam/β‐lactamase inhibitor combination developed to treat serious Gram‐negative bacterial infections; approved indications include complicated urinary tract infection, complicated intra‐abdominal infection, and hospital‐acquired pneumonia including ventilator‐associated pneumonia in patients ≥ 3 months old. Because of the predominantly renal clearance of ceftazidime and avibactam, dose adjustments (reductions) are required for patients with estimated creatinine clearance (CrCL) ≤ 50 mL/min. We describe the application of combined adult and pediatric population pharmacokinetic models in developing ceftazidime‐avibactam dose recommendations for pediatric patients ≥ 2 to